Live Breaking News & Updates on Progression free survival

Stay informed with the latest breaking news from Progression free survival on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Progression free survival and stay connected to the pulse of your community

Immutep Announces Positive Preliminary Topline Results From TACTI-003 Cohort B

Immutep Announces Positive Preliminary Topline Results From TACTI-003 Cohort B
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

France , United-states , Australia , Sydney , New-south-wales , Australian , Chris-basta , Immutep-limited , Nasdaq , Merck-sharp-dohme , Merck-co-inc , International-agency-for-research-on-cancer

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

Philadelphia , Pennsylvania , United-states , Theodore-laetsch , Tina-deignan , Novartis , Developmental-therapeutics-program , Olivier-le-moal , Evaluate-safety , Adolescent-patients-with , Advanced-accelerator , Therapeutic-area-head

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023

Biodexa Pharmaceuticals PLC: Preliminary Results for the Year Ended 31 December 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Russia , Israel , Spain , Ukraine , United-kingdom , California , San-francisco , Israeli , Russian-federation , American , Stephen-parker

PDCline Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDClung01 cancer vaccine

PDCline Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDClung01 cancer vaccine
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

France , Switzerland , United-states , Leuven , Region-flamande , Belgium , Poland , Germany , Netherlands , American , Eric-halioua , Johan-vansteenkiste

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 -- AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have...

United-states , American , Robert-edwards , Thomask-equels , Exchange-commission , Department-of-obstetrics , Immunotech-inc , Facebook , Gynecologic-oncology-research-at-magee-womens-hospital , University-of-pittsburgh-medical-center , Gynecology-reproductive-sciences , Linkedin

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | Company Announcement

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

United-states , American , Thomask-equels , Robert-edwards , Facebook , University-of-pittsburgh-medical-center , Gynecology-reproductive-sciences , Linkedin , Gynecologic-oncology-research-at-magee-womens-hospital , Exchange-commission , Immunotech-inc , Department-of-obstetrics

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Thomask-equels , Robert-edwards , Department-of-obstetrics , Immunotech-inc , Gynecologic-oncology-research-at-magee-womens-hospital , Gynecology-reproductive-sciences , University-of-pittsburgh-medical-center , Immune-checkpoint-blockade , Recurrent-ovarian , Pittsburgh-medical-center

AACR 2024: PDCline Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDClung01 Cancer Vaccine

LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDCline Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDClung01.

France , Switzerland , Netherlands , United-states , South-korea , Leuven , Region-flamande , Belgium , Poland , Germany , French , Belgian

AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I

Intermediary results of high dose PDClung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDClung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...

France , Switzerland , Germany , Belgium , Netherlands , Leuven , Region-flamande , United-states , Poland , American , Johan-vansteenkiste , Eric-halioua

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors (IPSEY)

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors (IPSEY)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Denmark , Japan , China , United-states , Canada , Paris , France-general- , France , Danish , American , Luveltamab-tazevibulin , Sutro-biopharma